Mounjaro®

Mounjaro® is the brand name for tirzepatide, manufactured by Eli Lilly. It's FDA-approved for improving blood sugar control in adults with type 2 diabetes and is also prescribed off-label for weight management. Mounjaro® works by activating both GLP-1 and GIP receptors, creating a dual-action effect that helps regulate appetite, slow digestion, and improve insulin sensitivity.

At altRx, Mounjaro® is available through licensed clinicians who evaluate your health history and goals to determine if it's the right choice for you. Treatment is managed through convenient telehealth consultations with ongoing support throughout your journey.

Mounjaro® is the FDA-approved brand-name version manufactured by Eli Lilly, while compounded tirzepatide is prepared by specialized pharmacies. Both contain the same active ingredient—tirzepatide—but differ in formulation, delivery method, and cost.

Mounjaro® comes in pre-filled, single-dose pens with precise dosing, while compounded versions typically come in vials requiring manual preparation. Mounjaro® is generally more expensive but covered by some insurance plans, while compounded tirzepatide offers a more affordable self-pay option. Your clinician can help you choose based on your budget, preferences, and insurance coverage.

Mounjaro®'s dual-action mechanism sets it apart from single-hormone GLP-1 medications. By activating both GLP-1 and GIP receptors, it addresses multiple metabolic pathways simultaneously. GLP-1 reduces appetite and slows stomach emptying, while GIP enhances insulin secretion and may improve fat metabolism.

Clinical trials (SURMOUNT-1) demonstrated that participants taking the highest dose of Mounjaro® lost an average of 22.5% of their body weight over 72 weeks. This dual-receptor activation creates synergistic effects that support not just weight loss, but also improved blood sugar control, reduced inflammation, and potential cardiovascular benefits.

Most users notice reduced appetite and cravings within the first few days of starting Mounjaro®. You'll likely feel fuller faster during meals and find it easier to resist snacking between meals. The sensation of satiety lasts longer, making portion control feel natural rather than restrictive.

Common initial side effects include mild nausea, occasional digestive discomfort, or changes in bowel habits—these typically improve after 2-4 weeks as your body adjusts. Mounjaro® dosing starts low and increases gradually every 4 weeks, allowing your system to adapt while minimizing side effects. Many users report steady, sustainable weight loss alongside improved energy levels.

Administration: Once-weekly subcutaneous injection using pre-filled, single-dose pen
Dosing: Starts at 2.5mg weekly, increases every 4 weeks (2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg max)
Storage: Refrigerate unused pens (36-46°F); can be kept at room temperature (up to 86°F) for up to 21 days
Manufacturer: Eli Lilly and Company